Reduced expression of the immune checkpoint receptor PD1 on Tregs was also observed in the study of S Goel, which was consistent with the diminishment of the immune-suppressing function of Treg in BC TME (163), suggesting that CDK4/6 inhibitors may enhance the susceptibility of such tumors to immune checkpoint blockade (53). Here, CDK4 is linked to breast cancer.